Tresiba Rebound Effects When Stopping: What Every Woman Should Know

What "Rebound" Actually Means When You Stop Tresiba

The phrase "rebound effects" means different things depending on which medication you are discussing. With Tresiba, there is no pharmacological rebound in the sense of a counterregulatory hormone surge caused by the drug itself disappearing. What happens instead is straightforward: insulin degludec has a half-life of approximately 25 hours, and when you stop taking it, circulating insulin levels fall over roughly 3 to 5 days. Without basal insulin coverage, hepatic glucose production goes unchecked and blood glucose climbs. In type 1 diabetes, that rise can accelerate into diabetic ketoacidosis within hours.

That distinction matters clinically. A true pharmacological rebound (think beta-blockers and tachycardia, or clonidine and hypertensive crisis) involves a compensatory physiological response to the drug's absence. Stopping insulin degludec does not cause that. The danger is purely the loss of glycemic control, not an overshoot caused by the drug's mechanism reversing.

Why the Long Half-Life Changes the Timeline

Most other basal insulins, including glargine (Lantus, Basaglar) and detemir (Levemir), have half-lives of 12 to 19 hours. Tresiba's 25-hour half-life means the drug accumulates over the first 2 to 3 days of use and clears more slowly when stopped. Insulin degludec's pharmacokinetic profile shows a flat, ultra-long action duration of more than 42 hours at steady state. That same flat profile is the reason glucose does not spike the moment you miss a dose the way it might with a shorter-acting basal agent. You may feel falsely protected for the first 24 to 36 hours after stopping, then experience a rapid rise.

The First 72 Hours: What to Expect

• Hours 0 to 24: Residual degludec activity continues. Fasting glucose may remain near target.
• Hours 24 to 48: Basal coverage begins to fall meaningfully. Pre-meal readings start climbing, often 20 to 40 mg/dL above your usual range.
• Hours 48 to 72: Hepatic glucose output rises overnight. Fasting glucose can exceed 180 to 250 mg/dL in type 2 diabetes and rise higher in type 1.
• Beyond 72 hours: In type 1 diabetes, ketone production accelerates. DKA risk becomes real without an alternative insulin regimen.

How Women's Hormones Amplify the Hyperglycemic Rise

Insulin resistance is not static in women. It shifts with estrogen, progesterone, and cortisol changes across the menstrual cycle, pregnancy, and the menopausal transition. When you remove basal insulin on top of a high-resistance hormonal phase, the glucose rise is steeper and faster than population-average data (collected largely in men) would predict.

The Menstrual Cycle

In the luteal phase (roughly days 14 to 28), rising progesterone increases insulin resistance. A study published in Diabetes Care showed that women with type 1 diabetes require up to 20 percent more total daily insulin in the luteal phase compared with the follicular phase. If you stop Tresiba during the luteal phase without a bridge, glucose rises faster than it would mid-cycle. Plan transitions for the follicular phase when resistance is lower, if timing is within your control.

Perimenopause

Estrogen decline in perimenopause worsens insulin sensitivity independently of weight change. The Study of Women's Health Across the Nation (SWAN) found that insulin resistance increased significantly across the menopausal transition even after adjusting for body mass index and physical activity. Women stopping Tresiba during perimenopause may find that the glucose rebound is more severe and harder to correct than they experienced in their reproductive years. Prescribers should account for this when calculating bridge doses.

Type 2 Diabetes and PCOS

Polycystic ovary syndrome is the most common endocrine disorder in reproductive-age women, affecting 8 to 13 percent of women globally according to WHO estimates. Hyperinsulinemia is central to PCOS pathophysiology. Women with PCOS on insulin therapy have higher baseline insulin requirements relative to their weight, and stopping basal insulin without a metformin or GLP-1 bridge often leads to a faster and larger glycemic rebound than in women without PCOS.

The DEVOTE Trial: What the Data Actually Shows

The DEVOTE trial, published in the New England Journal of Medicine in 2017, randomized 7,637 people with type 2 diabetes at high cardiovascular risk to insulin degludec or insulin glargine U100 for approximately 2 years. The primary finding was cardiovascular non-inferiority: the rate of major adverse cardiovascular events (MACE) was 8.5 percent with degludec versus 9.3 percent with glargine (hazard ratio 0.91, 95% CI 0.78 to 1.06). Degludec also showed a significantly lower rate of severe nocturnal hypoglycemia, with 53 percent fewer events compared with glargine.

What DEVOTE Did Not Tell Us

Women made up approximately 29 percent of the DEVOTE population. The trial was not powered for sex-stratified analysis of hypoglycemia or MACE. This evidence gap is worth naming directly: the cardiovascular safety profile and the nocturnal hypoglycemia advantage of degludec over glargine have not been confirmed in a trial designed specifically for women, and the hormonal drivers of glucose variability in female participants were not measured or reported. Extrapolating the male-dominant findings to a perimenopausal woman with type 2 diabetes and PCOS requires clinical judgment, not assumption.

Hypoglycemia Risk Is Also Sex-Specific

Women with type 1 diabetes have higher rates of severe hypoglycemia than men. A registry analysis from Diabetologia found that female sex was an independent predictor of severe hypoglycemia. The hypoglycemia advantage Tresiba demonstrated in DEVOTE is relevant to women, but it applies while the drug is being used. Stopping it abruptly removes that protection entirely.

Pregnancy, Lactation, and Contraception: The Mandatory Section

Insulin degludec is a pregnancy Category B drug under the pre-2015 FDA classification system. Animal reproductive studies showed no harm, and the FDA label for Tresiba states that it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Human data remain limited. Most published experience with basal insulin in pregnancy is with glargine and detemir, the latter having the most strong human safety data in pregnancy.

Insulin Needs Across Pregnancy

If you are pregnant and using Tresiba, do not stop or change your insulin regimen without obstetric and endocrinology guidance.

• First trimester: Insulin sensitivity often increases transiently, reducing requirements. Some women experience hypoglycemia. The "rebound" risk if you stop here is paradoxically delayed by this sensitivity increase.
• Second trimester: Placental hormones drive progressive insulin resistance. Dose requirements typically rise 30 to 50 percent above pre-pregnancy levels.
• Third trimester: Requirements may double pre-pregnancy doses. Stopping basal insulin in the third trimester is associated with rapid hyperglycemia and risk of fetal harm.
• Labor and delivery: Many centers switch from degludec to insulin glargine or a continuous IV insulin infusion for better titration during labor. Discuss this transition with your care team by 36 weeks.
• Postpartum: Insulin requirements drop sharply within hours of delivery, often to below pre-pregnancy levels. A standing degludec dose calibrated for the third trimester will cause hypoglycemia postpartum if not reduced immediately.

Lactation

Insulin is a large-molecule peptide and is poorly absorbed orally. Transfer into breast milk is low, and any insulin that does transfer is likely degraded in the infant's gastrointestinal tract before systemic absorption. The LactMed database at NIH notes that insulin is not expected to cause harm in breastfed infants. Breastfeeding itself lowers maternal blood glucose (lactation consumes approximately 500 kcal per day), which means your degludec dose may need downward adjustment to avoid hypoglycemia during nursing sessions. Log your glucose before and 2 hours after feeding for the first 2 weeks postpartum.

Contraception

Insulin degludec is not a teratogen in the strict sense, and there are no mandatory contraception requirements tied to the drug itself. However, because uncontrolled diabetes causes serious fetal harm, ACOG Practice Bulletin No. 201 recommends preconception counseling and glycemic optimization before conception in all women with pregestational diabetes. If you are stopping Tresiba as part of a medication change and are sexually active with pregnancy possible, ensure your alternative regimen provides equivalent glycemic control before any gap in coverage.

Who Should and Should Not Stop Tresiba

Women Who May Have a Reason to Stop

• Type 2 diabetes achieving remission through significant weight loss (greater than 15 percent total body weight) or bariatric surgery, where basal insulin may no longer be required.
• Women transitioning to a closed-loop insulin pump system (hybrid closed-loop), where a separate basal insulin is no longer needed.
• Women prescribed Tresiba off-label for purposes that did not yield benefit.
• Postpartum women whose insulin requirements have dropped to near zero after delivery.

Women Who Should Not Stop Without a Direct Replacement

• Any woman with type 1 diabetes. Full stop. There is no safe period without basal insulin in type 1. Even a 24-hour gap creates DKA risk.
• Women with type 2 diabetes who are not in remission, regardless of how well-controlled they feel.
• Pregnant women. Do not stop any basal insulin in pregnancy without your endocrinologist or MFM specialist.
• Women in the luteal phase with type 1 diabetes who are planning a transition. Wait for the follicular phase if possible.

How to Stop Tresiba Safely: A Clinical Framework

Safe discontinuation of insulin degludec involves one of three strategies, chosen based on your diabetes type, current control, and the reason for stopping.

Strategy 1: Bridge to Another Basal Insulin

Switch directly without a gap. On the day you take your last Tresiba dose, start glargine or detemir at the same evening injection time. Most endocrinologists recommend starting the alternative basal at 80 percent of the degludec dose to account for residual degludec activity on days 1 to 2, then titrating up based on fasting glucose readings. The American Diabetes Association's Standards of Care 2024 recommends individualized dose adjustments when switching basal insulin formulations.

Strategy 2: Increase Bolus Insulin Coverage

For people on basal-bolus regimens in whom basal insulin is being removed and bolus is being increased, total daily dose should be recalculated by your prescriber. This is a higher-risk strategy and is rarely appropriate outside specialist supervision.

Strategy 3: Transition to Non-Insulin Therapy

In type 2 diabetes with good residual beta-cell function, stopping insulin may be supported by adding or intensifying GLP-1 receptor agonists (semaglutide, tirzepatide), SGLT2 inhibitors, or metformin. GLP-1 receptor agonists have shown benefit in women with obesity and type 2 diabetes and also have data in PCOS. A 2022 meta-analysis in Fertility and Sterility found that GLP-1 agonists reduced BMI, fasting insulin, and androgen levels in women with PCOS, making them a reasonable bridge in this population specifically.

Monitoring Protocol After Stopping

Whether you bridge or taper, glucose monitoring intensity should increase for at least 5 to 7 days after the last degludec dose.

• Check fasting glucose every morning.
• Check 2-hour post-meal glucose after at least one meal per day.
• Check bedtime glucose.
• For type 1 diabetes, check urine or blood ketones any time glucose exceeds 250 mg/dL.
• Contact your prescriber if fasting glucose exceeds 180 mg/dL on two consecutive mornings.

Tresiba Clinical Update: What Has Changed Since Approval

The FDA approved insulin degludec (Tresiba) in September 2015. Since then, several clinical developments are relevant to women.

Cardiovascular Safety Confirmed

DEVOTE (2017) confirmed cardiovascular non-inferiority to glargine in high-risk type 2 diabetes. No subsequent trial has overturned this finding. For women with type 2 diabetes and established cardiovascular disease, the cardiovascular risk profile of degludec is not a reason to prefer another basal insulin.

Flexible Dosing Confirmed in FLEX Trial

The FLEX trial, published in Diabetes Care in 2016, showed that insulin degludec could be dosed with a minimum of 8 hours between injections and a maximum interval of up to 40 hours without significantly worsening glycemic control or increasing hypoglycemia compared with fixed-time once-daily dosing. This flexible dosing schedule is clinically useful for women with irregular schedules, shift workers, and new mothers managing erratic feeding and sleeping patterns. It does not mean doses can be skipped entirely.

Real-World Data in Pregnancy Remain Limited

As of 2025, published case series and registry data on insulin degludec in pregnancy remain small. A 2020 review in Obstetrics and Gynecology noted that glargine and detemir have substantially more safety data in pregnancy than degludec, and most diabetes-in-pregnancy guidelines continue to favor detemir or glargine as first-line basal insulin in pregnancy. If you are planning a pregnancy and using degludec, discuss switching to detemir before conception with your endocrinologist.

Biosimilars Are Now Available

The FDA approved the first insulin degludec biosimilar, Awiqli (insulin icodec, a once-weekly insulin from Novo Nordisk), separately from degludec biosimilars in the strictest sense. A true degludec biosimilar pathway is underway in the US. Women switching between a branded and biosimilar basal insulin face the same bridging considerations described above.

Practical Glucose Targets for Women at Each Life Stage

Because population-level targets were set in mixed-sex trials, it is worth being explicit about where women may need individualized goals.

• Reproductive years (not pregnant): Fasting glucose 80 to 130 mg/dL; A1C below 7.0 percent for most women per ADA Standards of Care 2024.
• Preconception: A1C below 6.5 percent is associated with the lowest risk of major congenital malformations according to ACOG Practice Bulletin No. 201.
• Pregnancy: Fasting glucose below 95 mg/dL, 1-hour post-meal below 140 mg/dL, 2-hour post-meal below 120 mg/dL per ACOG guidelines.
• Perimenopause and post-menopause: A1C targets may be relaxed to below 7.5 to 8.0 percent in women with hypoglycemia unawareness or significant comorbidity, per ADA guidance on older adults.
• PCOS: No separate glycemic targets exist; standard type 2 targets apply, but insulin resistance management (metformin, GLP-1 agonists) should be prioritized alongside basal insulin decisions.

A Note on Hypoglycemia Fear and Stopping Insulin Without Telling Your Doctor

One underappreciated reason women stop Tresiba without telling their prescriber is fear of hypoglycemia, particularly nocturnal hypoglycemia. This is a rational fear grounded in real experience. A survey published in Diabetes Care found that fear of hypoglycemia was a primary driver of intentional insulin under-dosing in 20 to 30 percent of people with diabetes, with women more likely than men to report this behavior. Stopping degludec does not solve hypoglycemia fear. It trades one risk (low glucose) for a larger one (high glucose and DKA). If nocturnal hypoglycemia is driving you to consider stopping, ask your prescriber specifically about dose reduction, timing changes, or a continuous glucose monitor with alerts rather than discontinuation.

If cost is the barrier to continuing Tresiba, Novo Nordisk's Patient Assistance Program offers Tresiba at no cost for eligible uninsured patients, and a $99 per month cap program exists for commercially insured patients. Do not stop insulin for cost reasons without first calling your pharmacy or your prescriber's office.

Your next step: if you are considering stopping Tresiba for any reason, call your endocrinologist or diabetes care and education specialist before you miss a dose. Bring your last 2 weeks of glucose logs to the appointment. If you use a CGM, share the data report. A safe transition takes fewer than 15 minutes to plan and can prevent an emergency department visit.